ArticleBMC musculoskeletal disorders2026
Densitometric gains do not uniformly translate into clinical and psychosocial recovery: a 12-month multidimensional analysis of romosozumab therapy in postmenopausal osteoporosis.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough romosozumab produces substantial increases in bone mineral density (BMD), these densitometric gains may not necessarily translate into parallel clinical and psychosocial recovery. This study aimed to determine whether improvements in BMD reflect meaningful changes in pain, quality of life, kinesiophobia, and psychological status during romosozumab therapy, and to define the multidimensional structure of treatment response. Densitometric, clinical, and psychological responses were hypothesized to follow partially independent and region-specific trajectories.
methodsThis single-center cohort study included 46 postmenopausal women with osteoporosis treated with romosozumab and followed for 12 months. BMD was assessed by dual-energy X-ray absorptiometry at the lumbar spine, femoral neck, and total femur at baseline, 6, and 12 months. Pain (VAS), kinesiophobia (TAMPA), anxiety and depression (HADS), and quality of life (QUALEFFO-41) were evaluated at the same time points. Longitudinal changes were analyzed using repeated-measures ANOVA, correlation analyses, and exploratory hierarchical cluster analysis.
resultsBMD increased significantly at all skeletal sites over 12 months (all p < 0.001), with the greatest gains in the lumbar spine (~ 19%), followed by the femoral neck (~ 9%) and total femur (~ 6%). All clinical and psychosocial outcomes improved significantly (all p < 0.001; partial η² = 0.625-0.934). Changes in lumbar spine BMD showed statistically significant but modest associations with quality of life and depressive symptoms (r = - 0.304 to - 0.422, p < 0.05-0.01). Similarly, changes in femoral BMD parameters were modestly associated with pain (r = - 0.341 to - 0.481, p < 0.05-0.01) and kinesiophobia (r = - 0.308 to - 0.342, p < 0.05). Exploratory hierarchical cluster analysis identified distinct clusters separating patient-reported outcomes from densitometric parameters, with prior osteoporosis treatment history emerging as a bridging variable between these domains.
conclusionDensitometric gains during romosozumab therapy do not uniformly translate into patient-perceived recovery. Treatment response is multidimensional and region-specific, indicating that BMD alone is insufficient to capture therapeutic effectiveness. The region-specific pattern of these modest associations, femoral BMD changes with pain and kinesiophobia, and lumbar BMD changes with quality of life and depressive symptoms, supports the need for anatomically informed, patient-centered evaluation frameworks in osteoporosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.